CoChat

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

Open access
Felip, Enriqueta, Ardizzoni, Andrea, Ciuleanu, Tudor, Cobo, Manuel, Laktionov, Konstantin, Szilasi, Maria, Califano, Raffaele, Carcereny, Enric, Griffiths, Richard, Paz-Ares, Luis, Duchnowska, Renata, Garcia, Miriam Alonso, Isla, Dolores, Jassem, Jacek, Appel, Wiebke, Milanowski, Janusz, Van Meerbeeck, Jan P., Wolf, Juergen, Li, Ang, Acevedo, Angelic, Popat, Sanjay · 2020 · European Journal of Cancer
Cited by 162

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: CheckMate 171 (NCT02409368) is an open-label, multicentre, phase 2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer (NSCLC), conducted as part of a post-approval commitment to the European Medicines Agency (EMA). We report outcomes from this trial. METHODS: Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 and disease progression during/after ≥1 systemic treatment (≥1 being platinum-based chemotherapy) for advanced or metastatic disease were treated with nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity. The primary end-point was incidence of grade 3-4 treatment-related select adverse events (AEs). Other end-points included overall survival (OS) and safety. RESULTS: Of 811 patients treated, 103 had ECOG PS 2; 278 were aged ≥70 years and 125 were ≥75 years of age. Minimum follow-up was ~18 months. Safety was similar across populations; the most frequent grade 3-4 treatment-related select AEs in all treated patients were diarrhoea (1%), increased alanine aminotransferase (ALT, 1%), pneumonitis (0.7%), colitis (0.6%) and increased aspartate aminotransferase (AST, 0.5%). Median OS was similar in all treated patients and those aged ≥70 and ≥75: 10.0 months, 10.0 months and 11.2 months, respectively. Median OS was 5.2 months in patients with ECOG PS 2. CONCLUSION: These results suggest that nivolumab is well tolerated and active in patients with advanced, relapsed squamous NSCLC, including the elderly, with OS outcomes consistent with phase 3 data. In patients with ECOG PS 2, nivolumab had similar tolerability, but outcomes were worse, as expected in this difficult-to-treat, poor prognosis population. CLINICAL TRIAL REGISTRATION: NCT02409368.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2019.11.019

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 162

Metadata

Authors
Felip, E., Ardizzoni, A., Ciuleanu, T., Cobo, M., Laktionov, K., Szilasi, M., Califano, R., Carcereny, E., Griffiths, R., Paz-Ares, L., Duchnowska, R., Garcia, M. A., Isla, D., Jassem, J., Appel, W., Milanowski, J., Van Meerbeeck, J. P., Wolf, J., Li, A., Acevedo, A., & Popat, S.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2020-03
Volume
127
Pages
160-172
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3005530155
Cited by
162
References
6
FWCI
9.38
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. https://app.cochat.ai/papers/10.1016/j.ejca.2019.11.019
The paper
Felip, E., Ardizzoni, A., Ciuleanu, T., Cobo, M., Laktionov, K., Szilasi, M., Califano, R., Carcereny, E., Griffiths, R., Paz-Ares, L., Duchnowska, R., Garcia, M. A., Isla, D., Jassem, J., Appel, W., Milanowski, J., Van Meerbeeck, J. P., Wolf, J., Li, A., . . . Popat, S. (2020). CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2019.11.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.